Skip to content

Stereotaxis STXS Royalty — Revenue

Similar metrics at other companies

Aquestive Therapeutics, Inc. logo
AQSTRoyalty — Revenue
$0
Pfizer logo
PFERoyalty — Revenue
$396M+28.6%
HireQuest logo
HQIRoyalty — Revenue
$6.06M-12.9%
Sarepta Therapeutics, Inc. logo
SRPTRoyalty Revenue — Royalty Revenue
$4.18M+5.8%
Staar Surgical logo
STAARoyalty income
$508K
TEC
TECHRoyalty — Revenue
$4.97M-1.4%

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's royalty — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's royalty — revenue?
Stereotaxis (STXS) reported royalty — revenue of $0 in Q1 2026.
What does royalty — revenue mean?
This metric represents the revenue generated from licensing intellectual property or proprietary robotic technology to third parties. It reflects the company's ability to monetize its technological innovations through passive income streams without direct involvement in the end-user clinical procedure. This revenue source is typically high-margin and indicates the broader market adoption and value of the company's underlying patent portfolio.